DF2726A, a new IL-8 signalling inhibitor, is able to counteract chemotherapy-induced neuropathic pain
Genre
Journal ArticleDate
2019-12-01Author
Brandolini, LCastelli, V
Aramini, A
Giorgio, C
Bianchini, G
Russo, R
De Caro, C
D’angelo, M
Catanesi, M
Benedetti, E
Giordano, A
Cimini, A
Allegretti, M
Subject
Antineoplastic AgentsAntineoplastic Combined Chemotherapy Protocols
Cytokines
Humans
Interleukin-8
Molecular Targeted Therapy
Neuralgia
Oxaliplatin
Signal Transduction
Permanent link to this record
http://hdl.handle.net/20.500.12613/4308
Metadata
Show full item recordDOI
10.1038/s41598-019-48231-zAbstract
© 2019, The Author(s). Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect of several anti-neoplastics and a main cause of sensory disturbances in cancer survivors, negatively impacting patients’ quality of life. Peripheral nerve degeneration or small fibre neuropathy is generally accepted as the underlying mechanism in the development of CIPN. Recent evidence has contributed to clarify the determinant role of cytokines and chemokines in the process leading to neuronal hyperexcitability. Exposure to oxaliplatin triggers alterations in peripheral neuropathic pathways previously linked to IL-8 pathway. We investigated a novel selective inhibitor of IL-8 receptors, DF2726A, and showed its effects in counteracting CINP pathways, extending the relevance of the activation of IL-8 pathway to the class of platinum chemotherapeutics. Based on our results, we suggest that DF2726A might be a promising candidate for clinical treatment of CIPN conditions due to its efficacy and optimized pharmacokinetic/pharmacodynamic profile.Citation to related work
Springer Science and Business Media LLCHas part
Scientific ReportsADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/4290